A glutamatergic deficiency model of schizophrenia
- 1 February 1999
- journal article
- review article
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 174 (S37), 2-6
- https://doi.org/10.1192/s0007125000293574
Abstract
Although the presence of hyperdopaminergia has been demonstrated in the brains of people with schizophrenia, at least in some circumstances, other neurotransmitters are important in this disorder, and a glutamatergic deficiency model of schizophrenia is proposed. It is suggested that the amount of sensory input allowed to reach the cerebral cortex is restricted by an inhibitory effect of the striatal complexes on the thalamus, thereby protecting it from being overwhelmed. Several strands of evidence are presented to support the concept that a weakened glutamatergic tone increases the risk of sensory overload and of exaggerated responses in the monoaminergic systems that could result in psychosis.Keywords
This publication has 18 references indexed in Scilit:
- Neurotransmitter aberrations in schizophrenia: New perspectives and therapeutic implicationsLife Sciences, 1997
- Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography methodProceedings of the National Academy of Sciences, 1997
- Presynaptic dopaminergic function in the striatum of schizophrenic patientsSchizophrenia Research, 1997
- Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patientsThe Lancet, 1995
- The selective 5-HT2a receptor antagonist MDL 100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse ? implications for psychosisJournal of Neural Transmission, 1995
- The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted miceJournal of Neural Transmission, 1989
- The current status of the dopamine hypothesis of schizophreniaNeuropsychopharmacology, 1988
- Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic DrugsScience, 1976
- Receptor activity and turnover of dopamine and noradrenaline after neurolepticsEuropean Journal of Pharmacology, 1970
- Effect of Chlorpromazine or Haloperidol on Formation of 3‐Methoxytyramine and Normetanephrine in Mouse BrainActa Pharmacologica et Toxicologica, 1963